TITLE

Enzyme product approved for rare hand disorder

AUTHOR(S)
Traynor, Kate
PUB. DATE
March 2010
SOURCE
American Journal of Health-System Pharmacy;3/15/2010, Vol. 67 Issue 6, p416
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports on the approval of collagenase clostridium histolyticum or Xiaflex for injection from Auxilium Pharmaceuticals Inc. to treat Dupuytren's contracture in adults by the U.S. Food & Drug Adminstration (FDA). FDA says that Xiaflex is the first product with its labeling approved by the agency for the treatment of the rare disease affecting the hands and prevents the normal use of fingers. It states that Xiaflex consists of two purified microbial collagenases.
ACCESSION #
48478485

 

Related Articles

  • Auxilium's Xiaflex Setback May Be 'Last Box Checked.'. Osborne, Randy // BioWorld Today;6/19/2009, Vol. 20 Issue 117, p1 

    The article reports that Xiaflex, a formulation of collagenase enzyme for Dupuytren's contracture from Auxilium Pharmaceuticals Inc., will be subjected to an advisory review by the Food and Drug Administration (FDA) in the U.S. According to the Malvern, Pennsylvania-based company, the review...

  • Auxilium Files BLA for Dupuytren's Contracture.  // Bioworld Week;3/9/2009, Vol. 17 Issue 10, p3 

    The article reports on the submission of Auxilium Pharmaceuticals Inc.'s license application for its Xiaflex, a formulation of collagenase enzyme in the U.S. It notes that the drug will be the first pharmacological therapy for Dupuytren's contracture, when the Food and Drug Administration will...

  • New indication. STEIN, JULIANNE // Drug Topics;Jan2014, Vol. 158 Issue 1, p83 

    The article reports on the approval of the Xiaflex (collagenase clostridium histolyticum) injection from pharmaceutical company Auxilium Pharmaceuticals Inc. by the U.S. Food and Drug Administration (FDA) in 2014.

  • Financings Roundup.  // BioWorld Today;10/2/2009, Vol. 20 Issue 190, p6 

    This article reports that Auxilium Pharmaceuticals Inc. of Malvern, Pennsylvania culminated its public stock offering and has generated net proceeds amounting to 115.7 million U.S. dollars. Auxilium sold 3.45 million shares for 34.50 U.S. dollars each. The company continues to wait for a U.S....

  • Auxilium Files Xiaflex BLA, Seeks Nod in Dupuytren's Contracture. Boggs, Jennifer // BioWorld Today;3/4/2009, Vol. 20 Issue 41, p1 

    This article reports on a biologics license application submitted by Auxilium Pharmaceuticals Inc. to the U.S. Food & Drug Administration for the approval of its Xiaflex in Dupuytren's contracture. Xiaflex is a formulation of collagenase enzyme. Dupuytren's contracture is a rare condition...

  • Auxilium's Xiaflex Setback May Be 'Last Box Checked'.  // Bioworld Week;6/23/2009, Vol. 17 Issue 25, p5 

    The article reports the advisory review to be held for Xiaflex, a formulation of collagenase enzyme developed by Auxilium Pharmaceutical Inc. for treatment of Dupuytren's contracture. Auxilium has blamed administration at the U.S. Food and Drugs Administration (FDA) for this blow. William...

  • FDA actions. Elliott, William T. // Primary Care Reports;Jun2012 Pharmacology Watch, p2 

    The article reports that the FDA has approved Avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction (ED), and requires a labeling change on finasteride which is a Merck's testosterone blocker.

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jun2012, Vol. 47 Issue 6, p471 

    Several tables are presented which provide data related to drug approvals, subsmission, and labeling which include the new drugs being approved by the U.S. Food and Drug Administration (FDA) from March 17 to April 13, 2012, newly FDA-approved dosage forms and indications from March 17 to April...

  • Auxilium 'Finally' Wins Xiaflex Approval for Rare Hand Disease. Young, Donna // BioWorld Today;2/4/2010, Vol. 21 Issue 23, p1 

    This article reports on the increase in shares of Auxilium Pharmaceuticals Inc. on February 3, 2010 following the approval given by the U.S. Food and Drug Administration (FDA) to the firm's Xiaflex drug indicated to treat Dupuytren's contracture. Dupuytren's contracture is a progressive...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics